Eli Lilly and Company (LLY) Tuesday said its Kisunla for the treatment of adults with early symptomatic Alzheimer's disease has been approved by the Ministry of Health, Labour and Welfare Japan.
The approval was based on results from TRAILBLAZER-ALZ 2 Phase 3 study, in which treatment with Kisunla significantly slowed decline in memory, thinking, and daily functioning in patients with early symptomatic Alzheimer's disease.
Lilly said Japan is the second major market in which Kisunla was approved after the U.S., where the drug was approved in July this year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.